학술논문
Efficacy and safety of long-acting cabotegravir compared with daily oral tenofovir disoproxil fumarate plus emtricitabine to prevent HIV infection in cisgender men and transgender women who have sex with men 1 year after study unblinding: a secondary analysis of the phase 2b and 3 HPTN 083 randomised controlled trial
Document Type
Article
Author
Landovitz, R.J.; Kofron, R.M.; Hanscom, B.S.; Donnell, D.; Berman, R.; Clement, M.E.; Tran, H.V.; Eron, J.J.; Cohen, M.S.; Kallas, E.G.; Magnus, M.; Sued, O.; Sanchez, J.; Scott, H.; del Rio, C.; Fields, S.D.; Marzinke, M.A.; Eshleman, S.H.; Piwowar-Manning, E.M.; Richardson, P.A.; Sullivan, P.A.; Hendrix, C.W.; Spinelli, M.A.; Lucas, J.P.; McCauley, M.; Anderson, P.L.; Adeyeye, A.; Rooney, J.F.; Rinehart, A.R.; Grinsztejn, B.
Source
In: The Lancet HIV . (The Lancet HIV, December 2023, 10(12):e767-e778)
Subject
Language
English
ISSN
23523018